You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
The Seattle firm saw consumables and collaboration revenues fall, however, the GeoMx spatial transcriptomics platform grew instrument revenue.
The firm remains on track to ship its first NGS-enabled instruments, along with its new cancer transcriptome atlas panel covering more than 1,800 genes, during Q3.
The company said its product and services revenues were about $24.5 million for the quarter, 15 percent higher than the same period last year.
The firm said current adoption is robust, but enabling readout on NGS instruments this summer will be crucial to opening a much larger customer base.
The company plans to market its GeoMx instruments for broader, more discovery-oriented research with a sequencing-based readout.
NanoString logged $30.6 million in revenues in the third quarter, beating the Wall Street estimate of $28.1 million.
New publications have provided more detailed examples of the platform's research utility and hinted at future clinical applications in immuno-oncology.
Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
Time magazine looks into how liquid biopsies are changing cancer care.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.